OncoSil Medical LtdASX: OSL

AGM Chairman's Address and CEO & MD Presentation

· Issued by OncoSil Medical Ltd via ASX

Filed with ASX · · 16 pages · English

Summary by 6ix AI

OncoSil Medical Ltd has released the Chairman's address and CEO presentation for its Annual General Meeting, detailing significant achievements and transitions for the company during the past financial year. The address highlights the approval of the OncoSil device for treating pancreatic cancer and distal cholangiocarcinoma, marking a pivotal moment for commercial expansion in major markets. The company reported substantial growth in unit sales and revenue, alongside important regulatory milestones that position it for future success. Looking ahead, OncoSil aims to launch its product in the United States and Australia while expanding its clinical applications and commercial adoption across Europe.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX Announcement 18 November 2026 Chairman’s Address to 2026 Annual General Meeting Sydney, Australia – 18 November 2026: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable...

OncoSil Medical Ltd on 6ix

In the deck

Earlier from OncoSil Medical

Later from OncoSil Medical

All OncoSil Medical news releases